331 related articles for article (PubMed ID: 34367732)
21. The tumor immune composition of mismatch repair deficient and Epstein-Barr virus-positive gastric cancer: A systematic review.
Bos J; Groen-van Schooten TS; Brugman CP; Jamaludin FS; van Laarhoven HWM; Derks S
Cancer Treat Rev; 2024 Jun; 127():102737. PubMed ID: 38669788
[TBL] [Abstract][Full Text] [Related]
22. LAG3 and TIGIT Expression on Tumor-Infiltrating Lymphocytes in Cutaneous Melanoma.
Naimy S; Bzorek M; Eriksen JO; Løvendorf MB; Litman T; Dyring-Andersen B; Gjerdrum LMR
Dermatology; 2024; 240(1):156-163. PubMed ID: 37952520
[TBL] [Abstract][Full Text] [Related]
23. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.
Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S
Front Immunol; 2022; 13():974581. PubMed ID: 36159860
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer.
Pereira MA; Ramos MFKP; Faraj SF; Dias AR; Yagi OK; Zilberstein B; Cecconello I; Alves VAF; de Mello ES; Ribeiro U
J Surg Oncol; 2018 Apr; 117(5):829-839. PubMed ID: 29534305
[TBL] [Abstract][Full Text] [Related]
25. Tumor-Infiltrating T Cells in EBV-Associated Gastric Carcinomas Exhibit High Levels of Multiple Markers of Activation, Effector Gene Expression, and Exhaustion.
Salnikov M; Prusinkiewicz MA; Lin S; Ghasemi F; Cecchini MJ; Mymryk JS
Viruses; 2023 Jan; 15(1):. PubMed ID: 36680216
[TBL] [Abstract][Full Text] [Related]
26. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.
Macek Jilkova Z; Aspord C; Kurma K; Granon A; Sengel C; Sturm N; Marche PN; Decaens T
Clin Transl Gastroenterol; 2019 Jul; 10(7):e00058. PubMed ID: 31295151
[TBL] [Abstract][Full Text] [Related]
27. Association between Tim‑3 and Gal‑9 expression and gastric cancer prognosis.
Wang Y; Zhao E; Zhang Z; Zhao G; Cao H
Oncol Rep; 2018 Oct; 40(4):2115-2126. PubMed ID: 30106451
[TBL] [Abstract][Full Text] [Related]
28. Presence of Tim3
Klapholz M; Drage MG; Srivastava A; Anderson AC
J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692
[TBL] [Abstract][Full Text] [Related]
29. PIK3CA mutation subtype delineates distinct immune profiles in gastric carcinoma.
Choi S; Kim H; Heo YJ; Kang SY; Ahn S; Lee J; Kim KM
J Pathol; 2023 Aug; 260(4):443-454. PubMed ID: 37341658
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.
Koh J; Ock CY; Kim JW; Nam SK; Kwak Y; Yun S; Ahn SH; Park DJ; Kim HH; Kim WH; Lee HS
Oncotarget; 2017 Apr; 8(16):26356-26367. PubMed ID: 28412752
[TBL] [Abstract][Full Text] [Related]
31. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
Huang YH; Zhang CZ; Huang QS; Yeong J; Wang F; Yang X; He YF; Zhang XL; Zhang H; Chen SL; Zheng YL; Deng R; Lin CS; Yang MM; Li Y; Jiang C; Kin-Wah Lee T; Ma S; Zeng MS; Yun JP
J Hepatol; 2021 Apr; 74(4):838-849. PubMed ID: 33212090
[TBL] [Abstract][Full Text] [Related]
33. Intratumour T cells, their activation status and survival in gastric carcinomas characterised for microsatellite instability and Epstein-Barr virus infection.
Chiaravalli AM; Feltri M; Bertolini V; Bagnoli E; Furlan D; Cerutti R; Novario R; Capella C
Virchows Arch; 2006 Mar; 448(3):344-53. PubMed ID: 16261379
[TBL] [Abstract][Full Text] [Related]
34. Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer.
Dai C; Geng R; Wang C; Wong A; Qing M; Hu J; Sun Y; Lo AW; Li J
Mol Oncol; 2016 Dec; 10(10):1551-1558. PubMed ID: 27720576
[TBL] [Abstract][Full Text] [Related]
35. Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability.
Cho J; Chang YH; Heo YJ; Kim S; Kim NK; Park JO; Kang WK; Lee J; Kim KM
ESMO Open; 2018; 3(3):e000326. PubMed ID: 29636988
[TBL] [Abstract][Full Text] [Related]
36. Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability.
Ma C; Patel K; Singhi AD; Ren B; Zhu B; Shaikh F; Sun W
Am J Surg Pathol; 2016 Nov; 40(11):1496-1506. PubMed ID: 27465786
[TBL] [Abstract][Full Text] [Related]
37. Multiplex Immuno-Liquid Chromatography-Mass Spectrometry-Parallel Reaction Monitoring (LC-MS-PRM) Quantitation of CD8A, CD4, LAG3, PD1, PD-L1, and PD-L2 in Frozen Human Tissues.
Zhang Q; Salzler R; Dore A; Yang J; Ma D; Olson WC; Liu Y
J Proteome Res; 2018 Nov; 17(11):3932-3940. PubMed ID: 30277784
[TBL] [Abstract][Full Text] [Related]
38. An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.
Bottai G; Raschioni C; Losurdo A; Di Tommaso L; Tinterri C; Torrisi R; Reis-Filho JS; Roncalli M; Sotiriou C; Santoro A; Mantovani A; Loi S; Santarpia L
Breast Cancer Res; 2016 Dec; 18(1):121. PubMed ID: 27912781
[TBL] [Abstract][Full Text] [Related]
39. OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody.
Ohmura H; Yamaguchi K; Hanamura F; Ito M; Makiyama A; Uchino K; Shimokawa H; Tamura S; Esaki T; Mitsugi K; Shibata Y; Oda H; Tsuchihashi K; Ariyama H; Kusaba H; Oda Y; Akashi K; Baba E
Br J Cancer; 2020 May; 122(10):1507-1517. PubMed ID: 32203221
[TBL] [Abstract][Full Text] [Related]
40. TIM3
Chen K; Gu Y; Cao Y; Fang H; Lv K; Liu X; He X; Wang J; Lin C; Liu H; Zhang H; He H; Xu J; Li H; Li R
Br J Cancer; 2022 Jan; 126(1):100-108. PubMed ID: 34725458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
